id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2004-D-0301-0004,FDA,FDA-2004-D-0301,"Guidance for Industry on Fixed Dose Combination and Co-Packaged Drug
Products for Treatment of HIV; Availability",Notice,NAD-Notice of Availability of Data,2004-05-20T04:00:00Z,2004,5,2004-05-17T04:00:00Z,2004-07-20T03:59:59Z,2020-09-10T17:29:38Z,,0,0,0900006480472dd4
FDA-2004-D-0301-0001,FDA,FDA-2004-D-0301,FDA,Notice,NAD-Notice of Availability of Data,2004-05-20T04:00:00Z,2004,5,2004-05-17T04:00:00Z,2004-07-20T03:59:59Z,2020-09-19T20:34:04Z,,0,0,0900006480472dc9
FDA-2004-D-0301-0002,FDA,FDA-2004-D-0301,Guidance for Industry Fixed Dose Combination and Co-Packaged Drug Products for Treatment of HIV - DRAFT GUIDANCE,Other,Guidance,2004-05-20T04:00:00Z,2004,5,,,2020-09-15T01:02:11Z,,0,0,0900006480472dd0
FDA-2004-D-0301-0003,FDA,FDA-2004-D-0301,Guidance,Supporting & Related Material,GDL-Guidance,2004-05-20T04:00:00Z,2004,5,,,2008-04-12T00:35:45Z,,0,0,0900006480472dd3